All articles tagged with #insurance coverage
Mason Henderson, a 21-year-old from Texas, died after insurers denied coverage for a targeted cancer drug due to the rarity of his diagnosis. His case illustrates the gap between genomic testing capabilities and insurance reimbursement standards for rare tumors.
FDA approved Revolution Medicines’ pancreatic cancer drug Rasonque last month, a potential median-survival boost, but the closure of expanded-access programs and the slow pace of insurer coverage created a gap for patients like Juan Solano. The drug carries a near-$40,000 monthly price, and while patient-access programs and later insurer actions provided some relief, many families face a confusing, time-consuming path to obtain treatment after FDA clearance, underscoring a broader need for policy and payer systems to expedite coverage after approvals.
Pamela Anderson revealed she was diagnosed with hepatitis C in the late 1990s with an estimated 10-year life expectancy and disclosed the diagnosis in 2002. She believes she contracted the virus from sharing a needle with ex-husband Tommy Lee (he denies it). After a year-long interferon treatment with painful side effects, she paid out of pocket because insurance hadn’t covered the cure at the time. About a decade later a cure became available and she was able to become hepatitis C-free in 2015, using her amfAR Award of Courage speech to advocate for testing, reduce stigma, and raise awareness while continuing her acting career.
Insurers are shrinking GLP-1 weight-loss coverage ahead of 2027, but Eli Lilly just gained a concrete tool to defend diabetes reimbursement: the FDA expanded Mounjaro’s label to show cardiovascular risk reduction in high-risk adults with type 2 diabetes. The obesity coverage pullback remains, and payers are unlikely to be swayed by obesity claims, though the label provides medical-necessity language that could narrow exposure—especially with Medicare’s $50/month Bridge Program. Lilly’s growth remains strong (Q2 revenue up 91% to nearly $10B, full-year guidance raised), but the market hasn’t priced a full coverage shield into the stock yet.
A high-risk Washington woman faced a $1,200 bill for an annual breast MRI that was preapproved as a preventive measure, highlighting that federal rules don’t require free preventive MRIs for all cases (especially dense breasts) and that coverage varies—often leaving self-insured plans and state laws unable to guarantee no-cost imaging. The takeaway is to check state coverage rules, seek patient navigation, and shop around or time imaging to reduce out-of-pocket costs.
FDA approves Revolution Medicines’ oral daraxonrasib (Rasonque) for metastatic pancreatic adenocarcinoma after phase 3 results showing a 60% reduction in death risk and median survival of 13.2 months versus 6.7 with chemotherapy. The wholesale list price is about $39,800 for a 30‑day supply (roughly $477,000/year), but patients’ out‑of‑pocket costs vary with insurance; Medicare Part D and discounts can reduce costs by about 20–30%, and aid programs (e.g., Path) may offer low or zero copays for eligible patients. Side effects include rash, diarrhea, mucositis, nausea, fatigue, and edema. The drug is not a cure but offers a life‑extending option for a historically hard‑to‑treat cancer; about 67,000 pancreatic cancer diagnoses are expected in 2026.
A high‑risk woman was preapproved for an annual breast MRI, intended as preventive care, but she still received about $1,200 in charges after the scan; federal guidelines treat preventive breast MRIs differently based on whether a mammogram is abnormal, and self‑insured employer plans aren’t always bound by state rules, leaving patients to navigate deductibles and cost-sharing. The piece highlights gaps between preventive‑care recommendations and actual coverage and suggests checking state rules, using patient navigators, shopping around for pricing, and timing scans near the deductible year to minimize costs.
Many patients want to join clinical trials, but recruitment is hampered by geographic, time, and cost barriers, plus limited provider referrals and difficult trial searches. While ACA-mandated coverage helps with routine trial costs, incidental expenses and out-of-network issues can block participation. Policymakers and advocacy groups are pushing to streamline rules, fund travel/childcare support, and explore decentralized trials to expand access; patients should ask about trials, use search tools, and seek navigator help to identify feasible options.
Elective egg freezing remains expensive and poorly covered by insurance, with a single cycle averaging about $16,000 and total costs potentially reaching $47,000 when multiple cycles, storage, and implantation are included. Workplace benefits are the main source of coverage today, but many plans cap benefits and broad coverage is rare; only a minority of insurers and states provide comprehensive protections. If an employer pays for the benefit, it is typically treated as earned income and taxed, potentially increasing the tax bill, while medical-related preservation may be deductible.
Rep. Alexandria Ocasio-Cortez revealed she is freezing her eggs and paying thousands out of pocket, highlighting the lack of insurance coverage for the procedure. A proposed New York bill (S4497/A7339) would require such coverage and is the first of its kind, but has stalled in the Assembly after passing the Senate twice. The piece notes egg-freezing costs, the growing but uneven adoption of coverage by employers, and alternatives like Cofertility, while stressing the personal and policy dimensions of access to fertility preservation.
Colon cancer rates are rising among people in their 20s and 30s in the US, but adults under 45 often struggle to get insurance coverage for colonoscopies since the ACA mainly covers preventive screenings for those 45 and older. Diagnostic colonoscopies can be denied or costlier, leading to delays and out-of-pocket expenses (one case cited around $2,000). Doctors note referral loops and misattributions of symptoms contribute to late evaluations. Some experts suggest stool tests like Cologuard to expedite access, while the debate about lowering screening age continues due to capacity and disparities. Researchers also advocate broader study of cancer causes (the exposome) to inform policy and screening strategies.
Insurance constraints for the World Baseball Classic are sidelining several star players, with eight to ten Puerto Rican teammates potentially blocked from coverage and Team Puerto Rico weighing withdrawal; Francisco Lindor is among those denied due to elbow surgeries, as insurers tighten criteria after injuries in 2023. Rosters loom, and MLB/MLBPA are lobbying to loosen rules, while an age cap of 37 excludes some veterans and teams may have to absorb risk if players lack coverage.
Wisconsin physician Dr. Srividya Kidambi explains that the FDA-approved oral GLP-1 pill (semaglutide tied to SNAC) offers a cheaper, potentially easier alternative to injections like Wegovy, but must be taken fasting with a small amount of water and carries similar GI side effects. Insurance coverage for obesity remains inconsistent, supply shortages persist, and experts say the pill will complement rather than replace injections as the GLP-1 market is projected to grow dramatically into 2035.
The Department of Health and Human Services has updated cervical cancer screening guidelines to include self-collected vaginal samples for HPV testing and will require most private insurance plans to cover these tests without cost sharing, aiming to increase screening accessibility and reduce out-of-pocket costs.
Weight-loss drugs called GLP-1s are revolutionizing obesity treatment, with new developments including more effective medications, lower prices, and upcoming oral versions, though access remains limited due to high costs and insurance restrictions.